SERS-Based Serum Molecular Spectral Screening for Benign and Malignant Pulmonary Proliferative Nodules

"1. Screening interested participants should sign the appropriate informed consent (ICF) prior to completion any study procedures.~2. The investigator will review symptoms, risk factors, and other non-invasive inclusion and exclusion criteria.~3. The following is the general sequence of events during the 3 months evaluation period:~4. Completion of baseline procedures Participants were assessed for 3 months and completed all safety monitoring."